Monday , April 19 2021

▷ California Research Team Announces Promising Results for …



Santa Clara, California (PRNewswire / -) – The team of researcher Dr. Ing. The Rath Research Institute in California has developed a cancer vaccine that reduces tumor growth. The peptide-based vaccine targets a specific enzyme called metaloproteinase (MMP) responsible for tumor growth, metastasis and blood vessel formation in tumors (angiogenesis). Dr. Rath's research team showed that tested mice vaccinated with peptides containing specific MMP-2 and MMP-9 sequences and subsequently infected melanoma cancer cells had an average tumor reduction of about 76% compared with unvaccinated Animals from the control group. Especially, some vaccinated animals did not develop cancer at all.

The study was published in October 2018 in the online magazine Cellular Medicine and Natural Health.

Cancer is still the largest epidemic in the world. The disease each year causes more than 7 million deaths. This new approach to therapy has the potential to dramatically change these statistics. Compared with monoclonal antibodies (MABs) or biosimile molecules recently developed as anti-cancer agents, anti-MMP vaccine approach promises to be much more effective and more accessible in the global fight against the disease. While Mabs / Biosimilaries target a specific type of cancer, an anti-MMP vaccine can fight any type of cancer. Another advantage is that, unlike Mabs / Biosimilara, where one or two times monthly injection is usually required, the anti-MMP vaccine should only be injected once, and vaccination after several years is necessary.

If successful, the anti-MMP vaccine could be offered to patients from national or international health care institutions at a reasonable price.

To make this valuable technology accessible to most patients and peoples around the world, Dr. Rath's research institute applied for patent patents in many countries. The Institute asks public and state research institutions and other non-profit institutions to develop this promising technology with the aim of successful treatment, preventive suppression, and finally cancer elimination.

Source: https://www.jcmnh.org/peptide-vaccines-directed-against-human-metalloproteinases-mmps-with-anti-tumor-efficacy-in-vitro-and-in-vivo/

LOUSE. Patent no. 8003110 and 8067009

Photo – https://mma.prnewswire.com/media/780637/Dr_Rath_Cancer_Vaccine.jpg

Press contact:

Dr. Alexandra Niedzwiecki
president
Dr. Rath Research Institute
E-Mail: [email protected]

Original Content: Dr. honey. Rath Research Institute, present the news actuell


Source link